Pulmonary Hypertension In Chronic Obstructive Pulmonary Disease: Pulmonary Hyperinflation, Gas Trapping And Disproportionate Pulmonary Hypertension.
Funder
National Health and Medical Research Council
Funding Amount
$103,583.00
Summary
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in Australia. Raised blood pressure in the lungs (pulmonary hypertension, PH) predicts a worse prognosis in patients with COPD. The mechanisms contributing to PH are incompletely understood. We aim to determine the role of lung hyperinflation in contributing to the development of PH in COPD. We also aim to identify a sub-group of patients that develop severe PH which may benefit from specific therapy.
Elucidating The Role And Potential For Therapeutic Targeting Of TLR7 In Emphysema And COPD
Funder
National Health and Medical Research Council
Funding Amount
$925,780.00
Summary
Emphysema is a major cause of illness and death and there are no effective treatments. It is caused by smoking that damages the airways and air sacs but how this occurs is not well understood. We have found that a new factor, called Toll-like receptor 7, is involved in emphysema. In this study we will now characterise its roles in this disease, work out how it induces emphysema and test new inhibitors (antibodies) that we have developed as treatments.
Genetic Approaches To Understand How Imbalanced Cytokine Signalling Drives The Pathogenesis Of Emphysema
Funder
National Health and Medical Research Council
Funding Amount
$519,715.00
Summary
Emphysema is a major component of Chronic Obstructive Pulmonary Disease (COPD), the fifth leading cause of death in Australia for which there is no effective treatment. We have discovered a specific mutation in a gene called gp130 that results in the formation of emphysema in mice. This finding allows us to understand the exact mechanisms by which this mutation causes emphysema, and therefore has the potential to uncover new strategies to design novel therapies against emphysema in humans.
Targeting Oxidant-dependent Mechanisms That Drive COPD And Its Co-morbidities
Funder
National Health and Medical Research Council
Funding Amount
$741,343.00
Summary
Chronic obstructive pulmonary disease (COPD) is a lung disease that is the 4th leading cause of death worldwide. There is currently no effective therapy to treat people with COPD, which costs the Australian community over $8.8 billion/year. Much of the disease burden and health care costs in COPD is associated with the management of its comorbidities (i.e other chronic medical conditions such as heart disease). This project will develop novel therapies to treat COPD and its comorbidities.
Identifying New Therapeutic Targets For Preventing The Induction And Progression Of COPD
Funder
National Health and Medical Research Council
Funding Amount
$649,314.00
Summary
Smoking leads to lung inflammation that causes emphysema, which is a major health problem in Australia. Once induced there is a progressive decline in health, which continues even after stopping smoking. There are no treatments that halt this decline. Recently small genes have been discovered that control inflammation. We may be able to control these small genes and stop the induction and progression of emphysema. This project may lead to a completely new way of preventing and treating emphysema ....Smoking leads to lung inflammation that causes emphysema, which is a major health problem in Australia. Once induced there is a progressive decline in health, which continues even after stopping smoking. There are no treatments that halt this decline. Recently small genes have been discovered that control inflammation. We may be able to control these small genes and stop the induction and progression of emphysema. This project may lead to a completely new way of preventing and treating emphysema.Read moreRead less
Targeting Oxidant-dependent Pathways To Improve Stroke Outcomes In COPD
Funder
National Health and Medical Research Council
Funding Amount
$1,069,574.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a major incurable global health burden and is the 4th largest cause of death worldwide. Patients with COPD are at increased risk for stroke and this is even higher in the weeks following a lung viral infection. The reason for this is unknown so the aim of this study is to determine why people with COPD are at increased risk for stroke and then develop novel treatments to prevent or reduce stroke in COPD patients.
Characterisation Of A Novel Signaling Network That Translates Early-life Respiratory Infection Into Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Bacterial and viral respiratory infections in early-life cause permanent damage to the lungs and reduce lung function in later life. They may also increase the risk of developing asthma and emphysema. These are substantial health problems in Australia. My project aims to identify how infections cause these effects. This will enable me to identify new therapeutic targets and develop new therapies for the prevention of chronic lung diseases.